Homology Medicines Inc. (NASDAQ:FIXX)’s traded shares stood at 0.32 million during the last session, with the company’s beta value hitting -0.45. At the close of trading, the stock’s price was $6.46, to imply a decrease of -2.42% or -$0.16 in intraday trading. The FIXX share’s 52-week high remains $15.24, putting it -135.91% down since that peak but still an impressive 8.05% since price per share fell to its 52-week low of $5.94. The company has a valuation of $373.07M, with an average of 0.43 million shares in intraday trading volume over the past 10 days and average of 448.02K shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for Homology Medicines Inc. (FIXX), translating to a mean rating of 1.60. Of 11 analyst(s) looking at the stock, 0 analyst(s) give FIXX a Sell rating. 1 of those analysts rate the stock as Overweight while 1 advise Hold as 9 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.6.
Homology Medicines Inc. (NASDAQ:FIXX) trade information
After registering a -2.42% downside in the last session, Homology Medicines Inc. (FIXX) has traded red over the past five days. The stock hit a weekly high of 7.74 this Friday, 10/08/21, dropping -2.42% in its intraday price action. The 5-day price performance for the stock is -16.97%, and -13.87% over 30 days. With these gigs, the year-to-date price performance is -42.78%. Short interest in Homology Medicines Inc. (NASDAQ:FIXX) saw shorts transact 2.95 million shares and set a 6.54 days time to cover.
Analysts on Wall Street suggest a consensus price target of $23.20, implying an increase of 72.16% to the stock’s current value. The extremes give us $8.00 and $35.00 for target low and target high price respectively. As such, FIXX has been trading -441.8% off suggested target high and -23.84% from its likely low.
Homology Medicines Inc. (FIXX) estimates and forecasts
Looking at statistics comparing Homology Medicines Inc. share performance against respective industry, we note that the company has outperformed competitors. Homology Medicines Inc. (FIXX) shares are -9.90% down over the last 6 months, with its year-to-date growth rate higher than industry average at 35.00% against 7.40%. Revenue is forecast to grow 3.20% this quarter before jumping 1.60% for the next one. The rating firms project that company’s revenue will grow 1,117.20% compared to the previous financial year.
Revenue forecast for the current quarter as set by 9 analysts is $720k. Meanwhile, for the quarter ending Dec 2021, a total of 9 analyst(s) estimate revenue growth to $720k.
Homology Medicines Inc. has its next earnings report out between November 08 and November 12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Homology Medicines Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Homology Medicines Inc. (NASDAQ:FIXX)’s Major holders
Homology Medicines Inc. insiders hold 12.61% of total outstanding shares, with institutional holders owning 69.78% of the shares at 79.85% float percentage. In total, 69.78% institutions holds shares in the company, led by 5AM Venture Management, LLC. As of Jun 29, 2021, the company held over 4.54 million shares (or 7.95% of shares), all amounting to roughly $32.98 million.
The next major institution holding the largest number of shares is Blackrock Inc. with 3.36 million shares, or about 5.88% of shares outstanding. As of the market price on Jun 29, 2021, these shares were worth $24.41 million.
We also have Price (T.Rowe) New Horizons Fund and Fidelity Select Portfolios – Biotechnology as the top two Mutual Funds with the largest holdings of the Homology Medicines Inc. (FIXX) shares. Going by data provided on Mar 30, 2021, Price (T.Rowe) New Horizons Fund holds roughly 1.26 million shares. This is just over 2.20% of the total shares, with a market valuation of $11.82 million. Data from the same date shows that the other fund manager holds a little less at 1.25 million, or 2.20% of the shares, all valued at about 9.11 million.